MedTrace Logo

Reversal of Cognitive Decline (ReCODE) Study

NCT03883633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-01-22

No results posted yet for this study

Summary

Prospective study on patients enrolled in the ReCODE treatment protocol

Conditions

Interventions

BEHAVIORAL

ReCODE Protocol

Functional medicine approach to address symptoms of Alzheimer's and cognitive decline

Sponsors & Collaborators

  • QuesGen Systems Inc

    lead OTHER

Principal Investigators

  • Ann Hathaway, MD · Ann Hathaway MD

  • Deborah Gordon, MD · Northwest Memory Center

  • Kat Toups, MD · Kat Toups MD

Eligibility

Min Age
45 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03883633 on ClinicalTrials.gov